Pathology, research and practice最新文献

{"title":"Interactions in hepatic tumor microenvironment: Potential targets and modulations for effective therapy","authors":"Farag M.A. Altalbawy ,&nbsp;Ahmed Hussein Zwamel ,&nbsp;Gaurav Sanghvi ,&nbsp;R. Roopashree ,&nbsp;Mukesh Kumari ,&nbsp;Aditya Kashyap ,&nbsp;S. Gayathri ,&nbsp;Rajashree Panigrahi","doi":"10.1016/j.prp.2025.156074","DOIUrl":"10.1016/j.prp.2025.156074","url":null,"abstract":"<div><div>The hepatic tumor microenvironment (TME) exhibits complex interactions among diverse cellular components. Hepatocellular carcinoma cells actively communicate with the surrounding stroma and extracellular matrix (ECM). These interactions create an immunosuppressive and pro-tumorigenic environment. Cancer-associated fibroblasts (CAFs) are able to liberate several factors that promote tumor progression and ECM. Metabolic reprogramming and hypoxia in TME influence tumor growth and response to antitumor drugs through bidirectional signaling between tumor and stromal cells. Similarly, activated stellate cells contribute to matrix remodeling and tumor expansion. Tumor-associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and Kupffer cells can support immune evasion. Recent studies have identified key molecular mediators in these cellular networks. Several targeting strategies show promise in preclinical models. These include immune checkpoint inhibitors (ICIs), immunomodulators, stromal cell modulators, and matrix-degrading agents. However, the effectiveness of conventional therapies remains limited by microenvironmental barriers. Recent progress in the knowledge of TME, nanoparticles, immunomodulators, and even natural-derived molecules with immunoregulatory effects has shown promise in preclinical studies. This review aims to analyze critical interactions within the hepatic TME and evaluate emerging therapeutic approaches that target these interactions for improved treatment outcomes.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156074"},"PeriodicalIF":2.9,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144254719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular epigenetics in the transition of white to brown fat","authors":"Shatakshi Chaturvedi ,&nbsp;Pankaj Chaturvedi ,&nbsp;Prakash Chandra Gupta ,&nbsp;Sudhir Kumar Awasthi ,&nbsp;Anuradha Kalani","doi":"10.1016/j.prp.2025.156073","DOIUrl":"10.1016/j.prp.2025.156073","url":null,"abstract":"<div><div>Obesity and related metabolic disorders represent a significant global health challenge. A promising therapeutic avenue involves fat browning, the conversion of energy-storing white adipose tissue (WAT) into thermogenic beige fat, which dissipates energy as heat. Since brown fat dissipates more energy than white fat it is commonly characterized by increased mitochondrial biogenesis and the expression of thermogenic genes to enhance energy expenditure. Although fat browning can have different mechanisms, this review focusses on epigenetic mechanisms that underline browning of fat. These epigenetic mechanisms comprise DNA methylation (DNMTs), histone modifications (HDACs, H3K27Me3) and non-coding RNA (miR133, miR26, miR34a) mediated regulation. These epigenetic mechanisms in turn are triggered by diet and exercise, environmental factors such as temperature, obesity and comorbidities such as diabetes and blood pressure. The triggered epigenetic mechanisms in turn trigger genes such as UCP1 which are associated with thermogenesis in adipocytes and hence fat browning. Brown/white fat communicate with neighbouring organs such as liver, heart, kidneys and blood vessels providing protective environment. This review highlights recent advances in the field, focusing on key epigenetic regulators and their impact on adipose tissue conversion and metabolic health.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156073"},"PeriodicalIF":2.9,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy","authors":"Mokhtar Rejili","doi":"10.1016/j.prp.2025.156075","DOIUrl":"10.1016/j.prp.2025.156075","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) continues to be a very aggressive subtype with few targeted therapy options. Antibody-drug conjugates (ADCs) and poly (ADP-ribose) polymerase inhibitors (PARPis) have been promising therapeutic strategies, each of which targets different vulnerabilities in TNBC cells. ADCs like sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) target cytotoxic payloads with specificity, whereas PARPis like olaparib, rucaparib, niraparib, and talazoparib cause synthetic lethality in homologous recombination repair (HRR)-deficient tumors. Recent clinical trials of SEASTAR and PETRA have evaluated ADC-PARPi combinations to enhance anti-tumor activity through DNA damage induction with the prevention of its repair. Early data demonstrate enhanced therapeutic outcomes, especially in BRCA-mutated and HRD-positive TNBC. Myelosuppression and adaptation of dosing regimens remain challenges to be addressed. Future directions include biomarker-driven patient selection, combination with immune checkpoint inhibitors, and advancement in next-generation ADCs. The synergistic potential of ADC-PARPi combinations provides a new avenue for overcoming TNBC resistance, enhancing treatment outcomes, and widening therapeutic strategies for this challenging disease.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156075"},"PeriodicalIF":2.9,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-based histopathological features of histological slides and clinical characteristics as a novel prognostic indicator in diffuse large B-cell lymphoma","authors":"Zheng Li ,&nbsp;Jiajie Shi ,&nbsp;Xiaolin Wu ,&nbsp;Zhongze Cui ,&nbsp;Beichen Liu ,&nbsp;Yueping Liu","doi":"10.1016/j.prp.2025.156071","DOIUrl":"10.1016/j.prp.2025.156071","url":null,"abstract":"<div><h3>Objective</h3><div>This study developed and validated a deep learning model based on clinical and histopathological features for predicting the outcomes of diffuse large B-cell lymphoma (DLBCL).</div></div><div><h3>Methods</h3><div>This study analyzed 194 whole slide images from 194 patients with DLBCL. Clinical characteristics and histopathological features of hematoxylin-eosin-stained sections were extracted using CellProfiler. These features were analyzed and validated. The prognostic value of these features was evaluated by Cox regression analysis, the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).</div></div><div><h3>Results</h3><div>A total of 1120 digital features were extracted using a fully automated process. Harrell’s concordance index of the clinicopathologic nomogram was significantly higher than that of the Pathomics score based nomogram (0.791 vs. 0.750). The clinicopathologic nomogram had higher accuracy in predicting overall survival (OS). The AUC of the Pathomics score based nomogram for 1-year and 2-year OS was significantly higher than that of the clinicopathologic nomogram (1-year OS: 0.892 vs. 0.810; 2-year OS: 0.824 vs. 0.764). Nonetheless, the clinicopathologic nomogram had a stronger ability to predict 3-year OS than the simple nomogram (AUC: 0.812 vs. 0.759). DCA confirmed that the clinicopathologic nomogram was a better predictor of long-term OS, improving clinical decision-making.</div></div><div><h3>Conclusion</h3><div>The nomogram based on clinical and histopathological features is a novel, non-invasive, and convenient method to predict OS in patients with DLBCL and can potentially predict responses to treatment.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156071"},"PeriodicalIF":2.9,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLAMF8 (BLAME) as a novel immune checkpoint: Implications for inflammation, autoimmunity, and oncology","authors":"Ahmed Husseni ,&nbsp;Farag M.A. Altalbawy ,&nbsp;Irwanjot Kaur ,&nbsp;Malathi H ,&nbsp;Laxmidhar Maharana ,&nbsp;Archana Dhyani ,&nbsp;Ashish Singh Chauhan ,&nbsp;Gulzoda Negmatova ,&nbsp;Jatin Sharma ,&nbsp;Khursheed Muzammil","doi":"10.1016/j.prp.2025.156072","DOIUrl":"10.1016/j.prp.2025.156072","url":null,"abstract":"<div><div>SLAMF8 is a structurally distinct member of the SLAM receptor family, lacking classical intracellular signaling motifs yet exerting broad immunomodulatory functions. Predominantly expressed in myeloid-derived cells, SLAMF8 orchestrates a spectrum of immune responses—modulating oxidative burst, phagocytosis, cellular trafficking, and receptor expression—through noncanonical signaling pathways. Its regulatory footprint spans both innate and adaptive immunity, influencing macrophage polarization, T cell development, and antigen presentation. Recent findings illuminate SLAMF8's pivotal involvement in disease contexts marked by chronic inflammation, immune dysregulation, and malignancy. Elevated SLAMF8 expression is linked to tumor progression, immune evasion, and resistance to immunotherapies in various cancers, while its dysregulation contributes to autoimmunity, cardiovascular injury, and infectious disease pathogenesis. Beyond its functional roles, SLAMF8 is emerging as a versatile biomarker—reflecting immune microenvironments, predicting treatment outcomes, and potentially guiding therapeutic strategies. This review synthesizes current insights into SLAMF8’s biological roles and clinical relevance, positioning it as a compelling interface between immune homeostasis and disease. As research deepens, SLAMF8 may redefine therapeutic approaches across oncology, immunology, and regenerative medicine.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156072"},"PeriodicalIF":2.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kynureninase expression is associated with immunologically hot tumors and better prognosis in IDO1/TDO2-expressing breast carcinomas","authors":"Alexandra Giatromanolaki ,&nbsp;Aliki Fiska ,&nbsp;Maria Koffa ,&nbsp;Michael I. Koukourakis","doi":"10.1016/j.prp.2025.156069","DOIUrl":"10.1016/j.prp.2025.156069","url":null,"abstract":"<div><div>Indoleamine-2,3-dioxygenase (IDO1) and Tryptophan-2,3-dioxygenase (TDO2) are key enzymes in the kynurenine pathway, regulating the metabolism of tryptophan into the immunosuppressive metabolite L-kynurenine. Kynureninase (KYNU), another enzyme in this pathway, metabolizes L-kynurenine and may abrogate IDO1/TDO2-mediated immunosuppression. We assessed the expression of IDO1, TDO2 and KYNU immunohistochemically in a series of 146 breast carcinomas (BCa). IDO1 and TDO2 were overexpressed in 61/146 (41.8 %) and 95/146 (65.1 %) cases, respectively, and this pattern was associated with a higher rate of lymph node involvement (p = 0.002 and p = 0.05, respectively). High KYNU expression was detected in 49/146 (33.6 %) cases. Linear regression analysis revealed significant positive associations between IDO1 and TDO2 (p = 0.002, r = 0.26), as well as IDO1 and KYNU (p = 0.03, r = 0.16). Notably, high IDO1/TDO2 expression correlated with poor lymphocytic infiltration in both the invasive front and inner tumor areas when KYNU was not expressed (p &lt; 0.01 and p = 0.007, respectively). Among patients with high IDO1/TDO2 expression, high KYNU levels were significantly associated with better prognosis (p = 0.03, HR 0.43, 95 %CI 0.16–0.82). These findings suggest that the immunohistochemical evaluation of IDO1, TDO2 and KYNU in BCa tissue samples is feasible, providing a triple-marker approach for prognostic assessment and may guide immuno-oncology trials targeting the kynurenine pathway.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156069"},"PeriodicalIF":2.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological significance of amniotic papillary folding in the fetal membrane of the placenta: A single-institution study","authors":"Keita Yoshida ,&nbsp;Tadao Nakazawa ,&nbsp;Azumi Kawabata ,&nbsp;Takuya Nagasaka ,&nbsp;Atsuko Hasegawa ,&nbsp;Feng Guo ,&nbsp;Di Wu ,&nbsp;Kenzo Hiroshima","doi":"10.1016/j.prp.2025.156070","DOIUrl":"10.1016/j.prp.2025.156070","url":null,"abstract":"<div><div>Amniotic lesions provide useful information regarding the conditions of the fetus and mother in the gestational period. We noticed a characteristic papillary, branching or ramifying structure of the amnion on the fetal membrane that we termed \"amniotic papillary folding\" (APF), which was identifiable on microscopic observation, but not macroscopically. Based on the morphological features, APF entirely comprises preexisting amnion and seems to result from misalignment of the amnion. Among 201 placentas submitted for histopathological examination, 88 placentas (43.8 %) displayed APF. From a clinical perspective, APF appeared more frequently in placentas from mothers with hypertensive disorders of pregnancy (HDP). Conversely, APF was significantly less frequent in mothers with gestational diabetes mellitus (GDM). APF tended to be infrequent among mothers with threatened miscarriage, non-reassuring fetal status (NRFS) or fetal growth restriction (FGR). Regarding the relevance to other pathological diagnoses, chorioamnionitis was significantly associated with a reduced frequency of APF, whereas placental infarction was associated with an increased frequency. Our results may imply that the histogenesis of APF is positively associated with retained activity of the fetus in the uterus. APF might be infrequently encountered under conditions in which the fetus is weakened with attenuated mobility, including threatened miscarriage, NRFS, FGR, and most prominently GDM. Although the mechanisms involved remain unclear, this unique amniotic structure may offer a marker for the status of fetal dynamics and abnormal maternal conditions.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156070"},"PeriodicalIF":2.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us?","authors":"Alessandro Caputo ,&nbsp;Valentina Angerilli ,&nbsp;Alessandro Gambella ,&nbsp;Vincenzo L’Imperio ,&nbsp;Giuseppe Perrone ,&nbsp;Chiara Taffon ,&nbsp;Massimo Milione ,&nbsp;Federica Grillo ,&nbsp;Luca Mastracci ,&nbsp;Alessandro Vanoli ,&nbsp;Paola Parente ,&nbsp;Matteo Fassan","doi":"10.1016/j.prp.2025.156068","DOIUrl":"10.1016/j.prp.2025.156068","url":null,"abstract":"<div><div>The increasing complexity of cancer diagnostics and treatment selection has placed a growing burden on pathologists, particularly in the evaluation of immunohistochemical (IHC) biomarkers. In gastroesophageal cancers (GEC), both adenocarcinoma and squamous cell carcinoma subtypes, multiple prognostic and predictive biomarkers must be assessed to guide therapy. These evaluations require meticulous scoring, are time-consuming, and suffer from inter- and intra-observer variability. Given the worldwide shortage of pathologists, artificial intelligence (AI)-based tools have emerged as a potential solution to enhance efficiency and accuracy in biomarker scoring. This review aims to answer the question captured in its title: can AI help us in IHC biomarker scoring in GEC, and if so, how? A search of PubMed and Google Scholar was conducted to identify relevant studies. The analysis reveals that AI has demonstrated promise in improving reproducibility and reducing pathologist workload for biomarkers such as PD-L1 and HER2, although its applications in GEC remain limited compared to other cancer types. In parallel, predictive computational approaches are emerging that could revolutionize biomarker scoring altogether. By alleviating the burdens of complex scoring systems and costly additional assays, AI could have the potential to significantly enhance pathology practice in GEC biomarker evaluation.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156068"},"PeriodicalIF":2.9,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the chick embryo area vasculosa and chorioallantoic membrane as experimental models to study angiogenesis and anti-angiogenesis","authors":"Domenico Ribatti","doi":"10.1016/j.prp.2025.156067","DOIUrl":"10.1016/j.prp.2025.156067","url":null,"abstract":"<div><div>The vascularized extraembryonic membranes of the chick embryo include the area vasculosa (AV) and the chorioallantoic membrane (CAM), both used to study angiogenesis and anti-angiogenesis. In this article we compare these two experimental models and show that AV may be more suitable for the screening of putative angiogenic and anti-angiogenic molecules in alternative to the CAM, more useful to study tumor growth, angiogenesis, and metastasis, and of the angiogenic activity of acellular scaffolds and organoids.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156067"},"PeriodicalIF":2.9,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving cell-free DNA detection in advanced-stage high-grade serous ovarian cancer using combined TP53 mutational status and copy number changes","authors":"Hein S. Zelisse ,&nbsp;Ymke van der Pol ,&nbsp;Florent Mouliere ,&nbsp;Frederike Dijk ,&nbsp;Johannes B.G. Halfwerk ,&nbsp;Banafsche Mearadji ,&nbsp;Ludo F.M. Beenen ,&nbsp;Roy J. Reinten ,&nbsp;Saskia A.G.M. Cillessen ,&nbsp;Gerrit K.J. Hooijer ,&nbsp;Malou L.H. Snijders ,&nbsp;Marc J. van de Vijver ,&nbsp;Mignon D.J.M. van Gent ,&nbsp;Constantijne H. Mom","doi":"10.1016/j.prp.2025.156038","DOIUrl":"10.1016/j.prp.2025.156038","url":null,"abstract":"<div><div>Circulating tumor DNA (ctDNA) is a promising biomarker in patients with high-grade serous ovarian cancer (HGSOC). However, the detection rate of <em>TP53</em> mutations in ctDNA of HGSOC patients has previously been shown to be inadequate. Given the prevalence of copy number aberrations (CNAs) in HGSOC, this study aimed to improve ctDNA detection by combining <em>TP53</em> sequencing with shallow whole-genome sequencing (sWGS), and to evaluate the correlation with clinicopathological features and survival outcomes. This exploratory, retrospective cohort study included 53 advanced-stage HGSOC patients, comprising 18 treatment-naive patients and 35 patients treated with two neoadjuvant chemotherapy cycles. <em>TP53</em> targeted sequencing was integrated with sWGS (&lt;5x coverage) for CNA estimation using ichor copy number aberration tumor fraction (ichorCNA TF). <em>TP53</em> mutations were detected in 28 patients (52.8 %), and 17 patients (32.1 %) showed positive ichorCNA TF. Combining <em>TP53</em> mutation detection with ichorCNA TF identified 62.3 % (n = 33) of patients as ctDNA-positive, showing a trend towards improved detection compared to <em>TP53</em> mutation alone (p = .063). Treatment-naive patients exhibited higher <em>TP53</em> mutation (72.2 % vs. 42.9 %, p = .043) and ichorCNA TF (66.7 % vs. 14.3 %, p &lt; .001) detection rates compared to chemotherapy-treated patients. No correlations between ctDNA metrics and clinicopathological characteristics or survival outcomes were found. In conclusion, the integration of ichorCNA TF with <em>TP53</em> mutation analysis showed a trend towards improved ctDNA detection in advanced-stage HGSOC patients. Future studies should further explore ctDNA detection rates by ichorCNA TF and its potential clinical implications in HGSOC.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156038"},"PeriodicalIF":2.9,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}